Access cutting-edge hemophilia a treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Boston location
Preparing your pre-screening questions…
Access hemophilia a specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hemophilia a treatment provided free
Check if you qualify for this hemophilia a clinical trial in Boston, MA
No-Cost Study Care
Local to Boston
Convenient for MA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive damage that affects mobility and quality of life. Prophylactic FVIII administered intravenously every other day has been the standard of care treatment for HA for the past few decades. Sports and physical activity are generally encouraged in patients with hemophilia on appropriate prophylactic treatment to increase strength, prevent or decrease obesity, accrue and maintain bone density and encourage normal socialization. To ensure safety with participation in sports in persons with hemophilia A (PWHA), timing of FVIII administration is often adjusted to maximize FVIII at the time of sports. The exact factor level that is needed to safely participate in sports and minimize bleeding risk is not yet known. Based on clinical practice, infusion of FVIII to near the lower limit of normal right before participation in sports generally works to prevent bleeding. The study is looking at how well the newly approved medication Emicizumab works compared to Factor VIII to prevent bleeding in patients with Hemophilia A who play sports. The study will enroll children and adolescents who are already on Emicizumab or Factor VIII who are currently playing sports.
Sponsor: Wayne State University
Yes, this clinical trial (NCT05022459) has an active research site in Boston, MA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hemophilia a treatment options in Boston, MA, this clinical trial (NCT05022459) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hemophilia a specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hemophilia a clinical trials near you to find additional studies recruiting in your area.
See all pulmonary hypertension clinical trials recruiting in Boston — not just this study.
Browse Pulmonary Hypertension Trials in Boston →